Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

Nicotinic acetylcholine receptor subtype α4β2 is considered important in the regulation of attention and memory, and cholinergic degeneration is known as one pathophysiology of Alzheimer's disease. Brain amyloid-β protein deposition is also a key pathological marker of Alzheimer's disease. Recent amyloid-β imaging has shown many cognitively normal subjects with amyloid-β deposits, indicating a missing link between amyloid-β deposition and cognitive decline. To date, the relationship between the α4β2 nicotinic acetylcholine receptor and amyloid-β burden has not been elucidated in vivo. In this study we investigated the relation between α4β2 nicotinic acetylcholine receptor availability in the brain, cognitive functions and amyloid-β burden in 20 non-smoking patients with Alzheimer's disease at an early stage and 25 age-matched non-smoking healthy elderly adults by measuring levels of α4β2 nicotinic acetylcholine receptor binding estimated from a simplified ratio method (BPRI) and Logan plot-based amyloid-β accumulation (BPND) using positron emission tomography with α4β2 nicotinic acetylcholine receptor tracer (18)F-2FA-85380 and (11)C-Pittsburgh compound B. The levels of tracer binding were compared with clinical measures for various brain functions (general cognition, episodic and spatial memory, execution, judgement, emotion) using regions of interest and statistical parametric mapping analyses. Between-group statistical parametric mapping analysis showed a significant reduction in (18)F-2FA-85380 BPRI in the cholinergic projection region in patients with Alzheimer's disease with a variety of (11)C-Pittsburgh compound B accumulation. Spearman rank correlation analyses showed positive correlations of (18)F-2FA-85380 BPRI values in the medial frontal cortex and nucleus basalis magnocellularis region with scores of the Frontal Assessment Battery (a test battery for executive functions and judgement) in the Alzheimer's disease group (P < 0.05 corrected for multiple comparison), and also positive correlations of the prefrontal and superior parietal (18)F-2FA-85380 BPRI values with the Frontal Assessment Battery score in the normal group (P < 0.05 corrected for multiple comparison). These positive correlations indicated an in vivo α4β2 nicotinic acetylcholine receptor role in those specific functions that may be different from memory. Both region of interest-based and voxelwise regression analyses showed a negative correlation between frontal (11)C-Pittsburgh compound B BPND and (18)F-2FA-85380 BPRI values in the medial frontal cortex and nucleus basalis magnocellularis region in patients with Alzheimer's disease (P < 0.05 corrected for multiple comparison). These findings suggest that an impairment of the cholinergic α4β2 nicotinic acetylcholine receptor system with the greater amount of amyloid deposition in the system plays an important role in the pathophysiology of Alzheimer's disease.

[1]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[2]  P. A. Peterson,et al.  beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. , 2000, The Journal of biological chemistry.

[3]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[4]  R. Schliebs,et al.  Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β-amyloid precursor protein , 2002, Brain Research.

[5]  M. Schwab,et al.  Nerve growth factor increases choline acetyl-transferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons , 1985, Neuroscience.

[6]  P. Roelfsema.  Attention—Voluntary Control of Brain Cells , 2011, Science.

[7]  M. Picciotto,et al.  Nicotinic Receptors in the Brain: Links between Molecular Biology and Behavior , 2000, Neuropsychopharmacology.

[8]  R. Quirion,et al.  Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. , 2002, Progress in neurobiology.

[9]  Steven A. Johnson,et al.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.

[10]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[11]  M. D'Andrea,et al.  Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease , 2002, Neuroscience.

[12]  M. Sarter,et al.  Article Prefrontal Acetylcholine Release Controls Cue Detection on Multiple Timescales , 2022 .

[13]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[14]  Elliot A Stein,et al.  Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380 , 2008, Journal of Nuclear Medicine.

[15]  Johannes Schwarz,et al.  Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. , 2009, Archives of general psychiatry.

[16]  D. Bertrand,et al.  Chronic Nicotine Exposure Upregulates Nicotinic Receptors by a Novel Mechanism , 2005, The Journal of Neuroscience.

[17]  P. Park,et al.  Aging elevates metabolic gene expression in brain cholinergic neurons , 2008, Neurobiology of Aging.

[18]  W. J. Jackson,et al.  Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement , 1995, Psychopharmacology.

[19]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[20]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[21]  J. Corwin,et al.  Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease , 1999, Psychopharmacology.

[22]  A. Nordberg,et al.  Neuroreceptor changes in Alzheimer disease. , 1992, Cerebrovascular and brain metabolism reviews.

[23]  I. Stolerman,et al.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion , 2002, Neuropharmacology.

[24]  Jean-Luc Anton,et al.  Region of interest analysis using an SPM toolbox , 2010 .

[25]  Kosha Ruparel,et al.  Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers , 2010, Biological Psychiatry.

[26]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[27]  N. Volkow,et al.  Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  P. Whitehouse,et al.  Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. , 1995, Alzheimer disease and associated disorders.

[29]  T. Sharma,et al.  Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) , 2006, Journal of psychopharmacology.

[30]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[31]  A. Wall,et al.  Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET , 2007, Psychopharmacology.

[32]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[33]  Katrin Amunts,et al.  Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain , 2008, NeuroImage.

[34]  M. D'Andrea,et al.  Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. , 2002, Neuroscience.

[35]  Y. Kuo,et al.  β-Amyloid Directly Inhibits Human α4β2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SH-EP1 Cells* , 2004, Journal of Biological Chemistry.

[36]  A. C. Collins,et al.  Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. , 1983, The Journal of pharmacology and experimental therapeutics.

[37]  F. Leslie,et al.  Co-expression of α7 and β2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons , 2003, Neuroscience.

[38]  Philippe Faure,et al.  Executive and social behaviors under nicotinic receptor regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Fathallah-Shaykh.  Malignant astrocytomas: a system disease. , 2010, Archives of neurology.

[40]  J Nucl Med , 2010 .

[41]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[42]  C. Vidal.  Nicotinic receptors in the brain , 1996, Molecular and chemical neuropathology.

[43]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[44]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[45]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[46]  G. Paxinos,et al.  Atlas of the Human Brain , 2000 .

[47]  Jean-Dominique Gallezot,et al.  In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  R. Myers,et al.  Spatial Normalization of PET Ligand Images , 1998, NeuroImage.

[49]  F. Jessen,et al.  Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. , 2008, Neuroscience letters.

[50]  M. Zoli,et al.  Brain nicotinic acetylcholine receptors: native subtypes and their relevance. , 2006, Trends in pharmacological sciences.

[51]  Michele Zoli,et al.  Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain , 1995, Nature.

[52]  Edythe D London,et al.  Graphical analysis of 2‐[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain , 2003, Synapse.

[53]  T. Robbins,et al.  Selective Behavioral and Neurochemical Effects of Cholinergic Lesions Produced by Intrabasalis Infusions of 192 IgG-Saporin on Attentional Performance in a Five-Choice Serial Reaction Time Task , 2002, The Journal of Neuroscience.

[54]  Svetlana I. Chefer,et al.  Cigarette Smoking Saturates Brain α4β2 Nicotinic Acetylcholine Receptors , 2006 .

[55]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[56]  Hiroyuki Okada,et al.  Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double‐tracer positron emission tomography study , 1999, Annals of neurology.

[57]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[58]  J. Berger-Sweeney.  The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers , 2003, Neuroscience & Biobehavioral Reviews.

[59]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[60]  Michael McKinney,et al.  Brain cholinergic vulnerability: relevance to behavior and disease. , 2005, Biochemical pharmacology.

[61]  Martin Sarter,et al.  Enhancement of Attentional Performance by Selective Stimulation of α4β2* nAChRs: Underlying Cholinergic Mechanisms , 2010, Neuropsychopharmacology.

[62]  H. Mansvelder,et al.  Nicotinic Acetylcholine Receptor β2 Subunits in the Medial Prefrontal Cortex Control Attention , 2011, Science.

[63]  J. Changeux,et al.  Increased neurodegeneration during ageing in mice lacking high‐affinity nicotine receptors , 1999, The EMBO journal.

[64]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[65]  Y. Kuo,et al.  beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. , 2004, The Journal of biological chemistry.

[66]  M. Kikuchi,et al.  Effects of Brain Amyloid Deposition and Reduced Glucose Metabolism on the Default Mode of Brain Function in Normal Aging , 2011, The Journal of Neuroscience.

[67]  Timo Grimmer,et al.  Clinical severity of Alzheimer's disease is associated with PIB uptake in PET , 2009, Neurobiology of Aging.

[68]  B. Hahn,et al.  Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats , 2003, Psychopharmacology.

[69]  Mitsuru Kikuchi,et al.  In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  Edythe D London,et al.  Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. , 2006, Archives of general psychiatry.

[71]  H Okada,et al.  Altered glucose metabolism in the hippocampal head in memory impairment , 1998, Neurology.

[72]  J. Rinne,et al.  A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease , 1991, Brain Research.

[73]  F. Jessen,et al.  Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain , 2008, Neuroscience Letters.

[74]  L. Butcher,et al.  The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease , 1989, Neuroscience Letters.

[75]  S. DeKosky,et al.  Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease , 2011, Neurology.

[76]  J. Baron,et al.  'In the course of time': a PET study of the cerebral substrates of autobiographical amnesia in Alzheimer's disease. , 2004, Brain : a journal of neurology.

[77]  Carmen Martin-Ruiz,et al.  Nicotinic receptor abnormalities in Alzheimer’s disease , 2001, Biological Psychiatry.

[78]  F. Leslie,et al.  Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. , 2003, Neuroscience.

[79]  Swen Hesse,et al.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[80]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[81]  Yasuomi Ouchi,et al.  Altered Brain Serotonin Transporter and Associated Glucose Metabolism in Alzheimer Disease , 2009, Journal of Nuclear Medicine.